University Hospital, Toulouse: Neoplasms, Plasma Cell trials

The registry lists 11 Neoplasms, Plasma Cell studies with University Hospital, Toulouse as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 2 4Phase 3 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.RecruitingNCT06846905
• Impact of Chemotherapeutic Treatments in Patients Aged 75 Years and Over Treated for Lymphoid Hematological MalignancyCompletedNCT05101759Not applicable
• Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaStatus unknownNCT03669445Phase 2
• Myeloma Treatment in Real LifeCompletedNCT03638232
• Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple MyelomaTerminatedNCT02897830Phase 2
• Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple MyelomaCompletedNCT02197221Phase 3
• Frontline Therapy in de Novo Multiple Myeloma Patients Under 65CompletedNCT01206205Phase 2
• Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 YearsCompletedNCT01191060Phase 3
• Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)CompletedNCT00642395Phase 2
• Maintenance Therapy Using Lenalidomide in MyelomaCompletedNCT00430365Phase 3
• IFM 99-02 Thalidomide in MyelomaCompletedNCT00222053Phase 3